Patient characteristics
| Age (y) | Sex | Coeliac disease | GFD | Response to GFD | EmA antibodies | AGA antibodies | Grade of enteropathy | Duration of symptoms (months) | Clonality duo (bp) | Clonality Tu/jejunum in UJ (bp) | Outcome (months) | |
| CD1–8 | 12–70 | 6F, 2M | + | + | + | 6+, 2ni | 8+ | III-IV | 2–384 | Poly | − | All alive |
| CoS 1 | 24 | F | − | + | − | − | − | III | 24 | Oligo | − | +28 |
| CoS 2 | 40 | F | + | + | + | ni | + | IV | 228 | Poly | − | Alive 108 |
| Col.ass. | 55 | F | − | + | − | ni | ni | III | 12 | Poly | − | Alive 94 |
| CVID | 32 | F | − | + | − | − | − | III | 15 | Poly | − | Alive 96 |
| Auto E | 18 | M | − | + | − | − | + | IV | 24 | Poly | − | Alive 50 |
| RS 1 | 51 | M | − | + | − | ni | − | III | 22 | Poly | − | Alive 46 |
| RS 2 | 34 | F | − | + | − | − | − | IV | 10 | Poly | − | Alive 86 |
| RS 3 | 64 | F | − | + | − | − | − | III | 31 | Poly | − | Alive 84 |
| RS 4 | 42 | F | − | + | − | ni | − | III | 5 | Poly | − | Alive 70 |
| RS 5 | 74 | F | − | + | − | ni | − | IV | 2 | Poly | − | +12 |
| RS 6 | 79 | M | + | + | + | + | + | III | 23 | Mo 200 | − | +2 |
| RS−Tu1 | 72 | F | + | + | + | − | − | III | 69 | Bi 208,209 | Bi 208,209 | Alive 72 |
| RS−Tu2 | 56 | F | + | + | + | ni | + | IV | 72 | Poly | Mo 208 | +19 |
| RS−Tu3 | 60 | M | + | + | + | + | + | IV | 12 | Mo 205 | Mo 205 | +1 |
| UJ 1 | 73 | M | + | + | + | − | − | III | 12 | Bi 205,214 | Bi 205,214 | +4 |
| UJ 2 | 50 | F | + | + | + | + | + | III | 33 | Mo 211 | Mo 211 | Alive 24 |
| EITCL 1 | 48 | F | + | + | − | ni | ni | III | 9 | Poly | Mo 202 | +60 |
| EITCL 2 | 58 | F | − | − | − | − | II | − | Mo 207 | Mo 207 | +16 | |
| EITCL 3 | 52 | M | + | + | + | − | ni | III−IV | 58 | Poly | Mo 206 | +3 |
| EITCL 4 | 54 | F | + | + | − | + | − | III | 0 | Poly | Mo 211 | Alive 45 |
| EITCL 5 | 71 | F | + | + | + | − | + | IV | 288 | Poly | Mo 206 | +10 |
| EITCL 6 | 53 | F | + | + | + | + | + | IV | 24 | Bi 196,212 | Bi 196,212 | +3 |
| EITCL 7 | 71 | F | + | + | + | − | + | III | 4 | Poly | Mo 207 | +80 |
| EITCL 8 | 76 | F | + | + | − | ni | ni | III | 60 | Mo 210 | Mo 210 | +2 |
| EITCL 9 | 50 | F | + | + | + | ni | ni | III | 240 | Mo 212 | Mo 212 | Surv 4 |
Results of antibody tests were undertaken during a normal diet.
F, female; M, male; CD, coeliac disease; GFD, gluten free diet; EmA, antiendomysium antibodies; AGA, IgA antigliadin antibodies; enteropathy, enteropathy in duodenal biopsies is graded according to the classification by Marsh; duration of symptoms, duration of symptoms in months until definite diagnosis; outcome, if patients are alive, duration of disease since date of diagnosis is stated in months; CoS, collagenous sprue; Col.ass., colitis associated sprue syndrome. CVID, common variable immunodeficiency; auto E, autoimmune enteropathy; RS, refractory sprue, RS-Tu, refractory sprue developing EITCL; ni, not investigated; +xy, died after xy months; clonality Tu, results of TCR-γ gene PCR from DNA from the overt lymphoma; poly, polyclonal; mo, monoclonal, lenght of dominant bands in base pairs; oligo, oligoclonal; bi, biclonal; bp, base pairs; UJ, ulcerative jejunitis.